glp-1 agonist and dpp-4 inhibitor Cardiovascular effects of the inhibitors fig2.gif

Description

Cell Mol Gastroenterol Hepatol

Acute Kidney Injury On the FDA label for Ozempic, acute kidney injury and worsening of chronic renal failure is listed as a potential adverse reaction

Seventy-three percent of semaglutide participants achieved at least 5% weight loss, compared with 18% on placebo

In the case that one has at least one medical condition resulting from obesity, like hypertension, diabetes, sleep apnea, etc., this drug could be used starting at a BMI of 27, which would be equivalent to a lower weight compared to healthier individuals

This guide aims to provide practical, supportive, and realistic advice on navigating dietary choices while using GLP-1 medications, focusing on strategies to maximize benefits and promote overall health throughout this journey